Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis
Completed
University of Pittsburgh
Phase 3
1995-12-01
OBJECTIVES:
I. Evaluate the safety and efficacy of oral iloprost, a prostacyclin analog, in patients with
Raynaud's phenomenon secondary to systemic sclerosis.
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis
Completed
National Center for Research Resources (NCRR)
Phase 3
1995-12-01
OBJECTIVES:
I. Evaluate the safety and efficacy of oral iloprost, a prostacyclin analog, in patients with
Raynaud's phenomenon secondary to systemic sclerosis.
Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease
Completed
National Cancer Institute (NCI)
Phase 2
2001-11-01
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the
development or recurrence of cancer. Iloprost may be effective in preventing lung cancer.
PURPOSE: This randomized phase II trial is studying how well iloprost works in preventing
lung cancer in patients who are at high risk for this disease.
Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease
Completed
University of Colorado, Denver
Phase 2
2001-11-01
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the
development or recurrence of cancer. Iloprost may be effective in preventing lung cancer.
PURPOSE: This randomized phase II trial is studying how well iloprost works in preventing
lung cancer in patients who are at high risk for this disease.
Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)
Completed
Actelion
Phase 2
2004-06-01
The purpose of this study is to determine the safety and efficacy of Iloprost in subjects
that have Pulmonary Arterial Hypertension who are concurrently taking bosentan (Tracleer TM).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
